Aegros secures funding for Macquarie Park Plasma Fractionation facility

Following a significant capital raise, biomedical company Aegros will complete its state-of-the-art Haemafrac® Plasma Fractionation facility by December 2025, at 5 Eden Park Drive, Macquarie Park.

Once operational, the plant will produce Plasma Derived Medicinal Products or “PDMPs”, for the Australian health system and for global export. These human-derived specialty Pharmaceuticals include Immunoglobulin, Hyperimmune Globulins and Albumin.

Haemafrac® was invented at Aegros and uses a radically different process to the existing long-established production methods. The process called “Tangential Flow Electrophoresis” uses unique membrane technologies to separate proteins in Human Plasma at therapeutic scale. As well as being a simpler and “greener” technology, Haemafrac® delivers very high production efficiencies, and other advantages related to product safety and purity.

In addition to developing its own pipeline of PDMPs, Aegros will undertake Contract or “Toll” Fractionation of Plasma in Macquarie Park, for overseas governments and other commercial partners.

Plasma Fractionation capability is very poorly developed or completely absent in many countries, often meaning patients are denied access to lifesaving drugs, or are forced to pay exorbitant prices for imported products. Aegros plans to help to alleviate this chronic problem.

In establishing its Haemafrac® precinct at Macquarie Park, Aegros becomes Australia’s 2nd Plasma Fractionator, and the only Fractionator in NSW.

As the business scales and expands, Aegros expects to grow to be a significant local employer and become a major voice in the Macquarie Park Innovation District.

Keep an eye out on Aegros website and LinkedIn for latest job opportunities in the clinical manufacturing and quality assurance areas.